These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33341195)

  • 1. Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Noe MH; Micheletti RG
    Clin Dermatol; 2020; 38(6):607-612. PubMed ID: 33341195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
    Chung WH; Hung SI
    Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinguishing between erythema multiforme major and Stevens-Johnson syndrome/toxic epidermal necrolysis immunopathologically.
    Iwai S; Sueki H; Watanabe H; Sasaki Y; Suzuki T; Iijima M
    J Dermatol; 2012 Sep; 39(9):781-6. PubMed ID: 22458564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis.
    Chung WH; Hung SI
    J Dermatol Sci; 2012 Jun; 66(3):190-6. PubMed ID: 22541332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Harr T; French LE
    Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [News in severe clinical adverse drug reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)].
    Martínez-Cabriales SA; Gómez-Flores M; Ocampo-Candiani J
    Gac Med Mex; 2015; 151(6):777-87. PubMed ID: 26581536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic Mediators in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Saeed HN; Chodosh J
    Semin Ophthalmol; 2016; 31(1-2):85-90. PubMed ID: 26959133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine.
    Chen CB; Wang CW; Chung WH
    Methods Mol Biol; 2022; 2486():37-54. PubMed ID: 35437717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Chung WH; Hung SI; Yang JY; Su SC; Huang SP; Wei CY; Chin SW; Chiou CC; Chu SC; Ho HC; Yang CH; Lu CF; Wu JY; Liao YD; Chen YT
    Nat Med; 2008 Dec; 14(12):1343-50. PubMed ID: 19029983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of Toxic Epidermal Necrolysis.
    Harris V; Jackson C; Cooper A
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent progress in research of pathogeneses of Stevens-Johnson syndrome and toxic epidermal necrolysis].
    Gao TT; Long Q
    Zhonghua Yan Ke Za Zhi; 2016 Sep; 52(9):708-13. PubMed ID: 27647252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiomic single-cell sequencing defines tissue-specific responses in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Gibson A; Ram R; Gangula R; Li Y; Mukherjee E; Palubinsky AM; Campbell CN; Thorne M; Konvinse KC; Choshi P; Deshpande P; Pedretti S; Fear MW; Wood FM; O'Neil RT; Wanjalla CN; Kalams SA; Gaudieri S; Lehloenya RJ; Bailin SS; Chopra A; Trubiano JA; ; Peter JG; ; Mallal SA; Phillips EJ
    Nat Commun; 2024 Oct; 15(1):8722. PubMed ID: 39379371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions.
    Su SC; Chung WH
    Toxins (Basel); 2014 Jan; 6(1):194-210. PubMed ID: 24394640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Abe R
    J Dermatol; 2015 Jan; 42(1):42-8. PubMed ID: 25355273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of Severe Cutaneous Adverse Reactions and a New Treatment Strategy].
    Saito Y; Nakamura R
    Yakugaku Zasshi; 2019; 139(12):1557-1562. PubMed ID: 31787645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Borchers AT; Lee JL; Naguwa SM; Cheema GS; Gershwin ME
    Autoimmun Rev; 2008 Sep; 7(8):598-605. PubMed ID: 18603022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Hasegawa A; Abe R
    F1000Res; 2020; 9():. PubMed ID: 32595945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN): could retinoids play a causative role?
    Mawson AR; Eriator I; Karre S
    Med Sci Monit; 2015 Jan; 21():133-43. PubMed ID: 25579087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Khalili B; Bahna SL
    Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
    Koh MJ; Tay YK
    Curr Opin Pediatr; 2009 Aug; 21(4):505-10. PubMed ID: 19474732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.